Alessandro Cignetti
YOU?
Author Swipe
View article: Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the <scp>AVALON</scp> study
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the <span>AVALON</span> study Open
View article: Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group Open
View article: Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study Open
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the best consolidative treatment for high-risk acute lymphoblastic leukemia (ALL). The Campus ALL study group analyzed the clinical outcomes of patients treated in the real-l…
View article: Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents Open
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.
View article: Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases Open
Background: Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy …
View article: Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study Open
The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) has significantly improved patients’ prognosis. Within the Campus ALL network we analyzed the outcome of adult Ph-ALL pati…
View article: Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study Open
Summary Blinatumomab is the first bi‐specific T‐cell engager approved for relapsed or refractory B‐cell precursor acute lymphoblastic leukaemia (B‐ALL). Despite remarkable clinical results, the effects of blinatumomab on the host immune ce…
View article: SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria
SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria Open
We thank the support of the Severe Aplastic Anemia and Infectious Disease working parties of the EBMT and the patients for participation.
View article: P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING
P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING Open
Background: Midostaurin in combination with standard chemotherapy represents the standard of care for the treatment of newly-diagnosed (ND) FLT3-mutated Acute Myeloid Leukemia (AML) patients. However, data on the effectiveness of upfront F…
View article: A venetoclax and azacitidine <scp>bridge‐to‐transplant</scp> strategy for <i>NPM1</i>‐<scp>mutated</scp> acute myeloid leukaemia in molecular failure
A venetoclax and azacitidine <span>bridge‐to‐transplant</span> strategy for <i>NPM1</i>‐<span>mutated</span> acute myeloid leukaemia in molecular failure Open
Summary NPM1 ‐mutated acute myeloid leukaemia ( NPM1 mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual disease (MR…
View article: Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients Open
Although chemotherapy (CHT) exposure is an established cause of telomere attrition, determinants of telomere length (TL) dynamics after chemotherapy are poorly defined. In this study, we analyzed granulocyte telomere dynamics in 34 adult l…
View article: Full chimaeric <scp>CAR</scp>.<scp>CIK</scp> from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers
Full chimaeric <span>CAR</span>.<span>CIK</span> from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers Open
Summary Cytokine‐induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti‐tumour activity and …
View article: Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Aryloxyaryl Moiety
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Aryloxyaryl Moiety Open
In recent years, human dihydroorotate dehydrogenase inhibitors have been associated with acute myelogenous leukemia as well as studied as potent host targeting antivirals. Starting from MEDS433 (IC50 1.2 nM), we kept improving t…
View article: CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia Open
View article: Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia Open
View article: Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells
Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells Open
Chronic myeloid leukemia stem cells (CML LSCs) are a rare and quiescent population that are resistant to tyrosine kinase inhibitors (TKI). When TKI therapy is discontinued in CML patients in deep, sustained and apparently stable molecular …
View article: Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Biphenyl Moiety
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Biphenyl Moiety Open
The connection with acute myelogenous leukemia (AML) of dihydroorotate dehydrogenase (hDHODH), a key enzyme in pyrimidine biosynthesis, has attracted significant interest from pharma as a possible AML therapeutic target. We recently…
View article: Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome Open
CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in CML patients, but CML LSCs seem insens…
View article: Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors
Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors Open
Combined direct antineoplastic activity and the long-lasting immunological effects of allogeneic hematopoietic cell transplant (HCT) can cure many hematological malignancies, but broad adoption requires non-relapse mortality (NRM) rates an…
View article: The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia
The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia Open
Dihydroorotate Dehydrogenase (DHODH) is a key enzyme of the de novo pyrimidine biosynthesis, whose inhibition can induce differentiation and apoptosis in acute myeloid leukemia (AML). DHODH inhibitors had shown promising in vitro and in vi…
View article: The Synergism Between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia
The Synergism Between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia Open
Background Dihydroorotate Dehydrogenase (DHODH) is a key enzyme of the de novo pyrimidine biosynthesis, whose inhibition was recently found to induce differentiation and apoptosis in acute myeloid leukemia (AML). DHODH inhibitors were prev…
View article: CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program Open
View article: A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning
A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning Open
The immunophenotype is a key element to classify B-cell Non-Hodgkin Lymphomas (B-NHL); while it is routinely obtained through immunohistochemistry, the use of flow cytometry (FC) could bear several advantages. However, few FC laboratories …
View article: Peripheral blood immune status at clinical onset correlates with severity of Coronavirus Disease 2019
Peripheral blood immune status at clinical onset correlates with severity of Coronavirus Disease 2019 Open
The Coronavirus Disease 2019 (COVID-19) pandemic is a global threat to healthcare systems, requiring hospitalization in sub intensive and intensive care for respiratory syndrome in 25-30% of patients and accounting for a lethality up to 15…
View article: Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia Open
In acute myeloid leukemia (AML), blasts lose their ability to differentiate into mature cells and to undergo apoptosis. Accordingly, a proapoptotic and differentiating therapy (arsenic and retinoic acid) has dramatically improved survival …
View article: Chronic myeloid leukemia stem cells
Chronic myeloid leukemia stem cells Open
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC). In humans a CML LSC is operationally-defi…
View article: Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors Open
Human dihydroorotate dehydrogenase ( hDHODH) catalyzes the rate-limiting step in de novo pyrimidine biosynthesis, the conversion of dihydroorotate to orotate. hDHODH has recently been found to be associated with acute myelogenous leukemia,…
View article: Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms Open
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the tre…